Corcept Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 1006.08, 1499.86, 1913.61, 2617.19, 3132.81 ], "ebit_estimate": [ 104.94, 576.7, 1264.15, 1448.16, 1891.75 ], "ebitda_estimate": [ 116.43, 278.9, 506.5, 822.6, 1201.3 ], "net_income_estimate": [ 85.73, 476.36, 709.72, 1182.02, 1542.73 ], "per_share_eps_estimate": [ 0.59, 2.61, 5.42, 9.46, 12.28 ], "eps_nri_estimate": [ 0.59, 2.92, 6.56, 9.46, 12.28 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 6.01, 9.35, 12.29, null, null ], "pretax_income_estimate": [ 103.88, 532.51, 882.59, 1467.46, 1914.45 ], "operating_cash_flow_per_share_estimate": [ 1.06, 0.59, 0.48, null, null ], "roa_estimate": [ 9, null, null, null, null ], "roe_estimate": [ 16.05, 31.81, 30.38, null, null ], "gross_margin_estimate": [ 98.23, 97.95, 98.2, 98.45, 98.5 ], "operating_cash_flow_estimate": [ 110.7, 61.62, 50.13, null, null ], "pettm_estimate": [ 157.06, 35.15, 16.95, 9.71, 7.48 ], "long_term_growth_rate_mean": 119.21, "long_term_revenue_growth_rate_mean": "37.22", "future_per_share_eps_estimate_growth": 104.68, "future_eps_nri_estimate_growth": 119.21, "future_revenue_estimate_growth": 37.22, "future_ebit_estimate_growth": 222.97, "future_ebitda_estimate_growth": 124.2, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 114.89, "future_pretax_income_estimate_growth": 155.78, "future_book_value_per_share_estimate_growth": 28.88, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 32.89, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -28 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 220.06, 274.29, 346.84, 322.9, 383, 423.55, 456.75 ], "ebit_estimate": [ 5.75, 41.82, 101.19, 19.2, 55.6, 80.7, 106.3 ], "ebitda_estimate": [ 35.24, 42.88, 93.85, null, null, null, null ], "net_income_estimate": [ -1.11, 36.81, 81.62, 16.6, 46, 65.7, 84.7 ], "per_share_eps_estimate": [ 0, 0.27, 0.62, 0.51, 0.87, 1.09, 1.27 ], "eps_nri_estimate": [ 0.01, 0.27, 0.62, 0.51, 0.87, 1.09, 1.27 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 5.06, 5.02, 4.98, null, null, null, null ], "pretax_income_estimate": [ -1.58, 44.3, 105.84, 21.2, 58.6, 83.7, 107.9 ], "operating_cash_flow_per_share_estimate": [ 0.27, 0.32, 0.66, null, null, null, null ], "roa_estimate": [ 1.1, 1.6, 6.7, null, null, null, null ], "roe_estimate": [ 1.6, 2.5, 11.5, null, null, null, null ], "gross_margin_estimate": [ 98.18, 98.18, 98.43, 98.15, 98.15, 98.15, 98.15 ], "operating_cash_flow_estimate": [ 28.2, 33.42, 68.93, null, null, null, null ], "pettm_estimate": [ 66.1, 40.69, 29.88, 24.67, null, null, null ], "long_term_growth_rate_mean": 119.21, "long_term_revenue_growth_rate_mean": "37.22", "future_per_share_eps_estimate_growth": 104.68, "future_eps_nri_estimate_growth": 119.21, "future_revenue_estimate_growth": 37.22, "future_ebit_estimate_growth": 222.97, "future_ebitda_estimate_growth": 124.2, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 114.89, "future_pretax_income_estimate_growth": 155.78, "future_book_value_per_share_estimate_growth": 28.88, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 32.89, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -28 }